Evoke Pharma Inc. reported a significant increase in net product sales for the first quarter of 2025, achieving a 77% year-over-year rise to $3.1 million. The growth is attributed to the sustained momentum driven by growing prescriber adoption and repeat patient use of GIMOTI®, the company's treatment for gastrointestinal disorders. The company also experienced a rise in operating expenses, with selling, general, and administrative expenses reaching approximately $4.3 million, compared to $3.1 million in the same quarter of the previous year, due to higher professional fees and increased reimbursement and profit-sharing activities with EVERSANA. Evoke Pharma reiterated its 2025 net product sales guidance of approximately $16 million, reflecting a projected 60% increase over 2024. The company's financial outlook is based on its current business performance, including recent growth in net product sales and assumptions about reimbursements and prescription fills. Factors outside of Evoke's control, such as global macroeconomic conditions and supply chain constraints, are also considered in their projections. In terms of corporate governance, Evoke Pharma appointed Greg Pyszczymuka to its Board of Directors, bringing his extensive experience in commercial strategy and revenue growth to aid in advancing the company's market position. Additionally, GIMOTI demonstrated strong momentum in the first quarter, with a 73% year-over-year increase in fill rate and a 44% increase in the total prescriber base, reflecting expanded interest and engagement among healthcare providers. As of March 31, 2025, the company had cash and cash equivalents of approximately $12.6 million, which is expected to fund operations into the second quarter of 2026.